Commerzbank Aktiengesellschaft FI raised its holdings in Boston Scientific Corporation (NYSE:BSX) by 33.5% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 20,775 shares of the medical equipment provider’s stock after acquiring an additional 5,209 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Boston Scientific were worth $515,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Prudential Financial Inc. raised its position in shares of Boston Scientific by 149.1% in the third quarter. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider’s stock valued at $138,928,000 after purchasing an additional 2,850,630 shares during the period. American Century Companies Inc. raised its position in shares of Boston Scientific by 28.9% in the third quarter. American Century Companies Inc. now owns 10,496,489 shares of the medical equipment provider’s stock valued at $306,183,000 after purchasing an additional 2,352,297 shares during the period. Sirios Capital Management L P raised its position in shares of Boston Scientific by 373.5% in the third quarter. Sirios Capital Management L P now owns 1,896,262 shares of the medical equipment provider’s stock valued at $55,314,000 after purchasing an additional 1,495,821 shares during the period. Lord Abbett & CO. LLC bought a new position in shares of Boston Scientific in the second quarter valued at approximately $40,460,000. Finally, Koch Industries Inc. raised its position in shares of Boston Scientific by 7,722.1% in the second quarter. Koch Industries Inc. now owns 964,072 shares of the medical equipment provider’s stock valued at $931,000 after purchasing an additional 951,747 shares during the period. Hedge funds and other institutional investors own 89.84% of the company’s stock.
In other news, SVP David A. Pierce sold 5,152 shares of the business’s stock in a transaction on Tuesday, January 9th. The shares were sold at an average price of $27.00, for a total value of $139,104.00. Following the sale, the senior vice president now owns 38,116 shares in the company, valued at approximately $1,029,132. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Valley Gold Master Fund L. Sun bought 408,006 shares of Boston Scientific stock in a transaction dated Tuesday, November 28th. The stock was purchased at an average price of $0.45 per share, for a total transaction of $183,602.70. Insiders sold a total of 177,032 shares of company stock worth $4,648,733 in the last three months. Insiders own 0.74% of the company’s stock.
Shares of Boston Scientific Corporation (BSX) traded down $0.27 during trading on Tuesday, reaching $25.91. 912,925 shares of the company’s stock traded hands, compared to its average volume of 9,695,891. The company has a market cap of $35,593.24, a price-to-earnings ratio of 370.71, a PEG ratio of 1.88 and a beta of 0.81. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. Boston Scientific Corporation has a 12-month low of $23.29 and a 12-month high of $29.93.
Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.34 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.34. The firm had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.39 billion. Boston Scientific had a net margin of 1.15% and a return on equity of 24.04%. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.30 EPS. sell-side analysts forecast that Boston Scientific Corporation will post 1.37 EPS for the current year.
A number of equities analysts have recently commented on the stock. Canaccord Genuity assumed coverage on shares of Boston Scientific in a research report on Tuesday, October 24th. They issued a “buy” rating and a $36.00 price target on the stock. Zacks Investment Research raised shares of Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 target price on the stock in a research report on Friday, October 20th. BMO Capital Markets boosted their target price on shares of Boston Scientific from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, October 27th. SunTrust Banks set a $34.00 target price on shares of Boston Scientific and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Finally, Barclays reaffirmed a “buy” rating and set a $32.00 target price on shares of Boston Scientific in a research report on Wednesday, January 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company’s stock. Boston Scientific presently has an average rating of “Buy” and an average target price of $31.00.
TRADEMARK VIOLATION NOTICE: This story was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally copied and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/13/boston-scientific-corporation-bsx-position-raised-by-commerzbank-aktiengesellschaft-fi.html.
About Boston Scientific
Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.
Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.